Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.

Abstract: The present disclosure relates to neutralizing anti-influenza monoclonal antibodies. The disclosure further relates to therapeutic uses of the isolated antibody. The antibodies are either directed against Hemagglutinin (HA) and Neuraminidase (NA) of Influenza H3N2.

Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.

Abstract: The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.

Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.

Abstract: The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.

Abstract: The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.

Abstract: The present invention provides a microfabricated device and methods for high throughput single cell screening of a heterogeneous population. The present invention is partly based upon but not limited to sorting by monitoring cell secreted factors that accumulate in time (hours, days, weeks) as cells are cultured in the microbubble well niche the architecture of which facilitate the accumulation. In certain embodiments, the device and method comprises a means to identify effective drugs for personalize therapeutics such as but not limited to discovery of monoclonal antibody therapeutics.

Abstract: A microfabricated device and method having a substrate with an array of curvilinear cavities that is used for high throughput single cell screening. The substrate of the device is preferably fabricated in a low elastic modulus polymer such as polydimethylsiloxane. The architecture of the cavity forms a small volume micro-niche that seeded cells can rapidly condition to promote survival and proliferation which can be monitored for hours to days to weeks. The cavity architecture allows independent assays to be conducted with minimal influence from nearest neighbor cavities. Methods are disclosed to use the device to, for example, screen single cells by clonal proliferation, clonal morphology, secreted factors, secretion rate, surface markers, and cell functional characteristics including but not limited to migration, drug resistance, the ability to block or promote signaling pathways, or to enhance opsonization.